Selective, reversible direct inhibitor of activated factor X (FXa). Blocks both free and prothrombinase-bound Xa → decreased thrombin generation. No antithrombin III cofactor required (distinct from heparin). Rapid onset (peak anticoagulant effect within 3 h). Andexanet alfa is the specific reversal agent.
Half-Life (t½)
PO: 11.5h
Dosing Guidelines
PO: Typical 5 mg (Range: 5–5 mg)
Target Organ Systems
immune-hematologic
Interactions
Warfarin (caution): Do not combine; overlapping anticoagulation. Transition protocols exist.